At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
Tralokinumab 300 mgbiological
Likely dose
Tralokinumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of a Single Subcutaneous Dose of Tralokinumab When Delivered as a 2 mL Injection at Different Flow Rates to Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Tralokinumab 300 mg for Asthma and Healthy Subjects or Volunteers. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) and tolerability of tralokinumab when delivered subcutaneously at different flow rates to healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Healthy Subjects or Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartMar 2014
Primary CompletionJul 2014
TodayJul 2026
First PostedMar 12, 2014
Enrollment StartMar 19, 2014
Primary CompletionJul 10, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.3 years ago
Interventions
Tralokinumab 300 mgbiological
Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.